세계의 광견병 백신 시장 규모, 점유율, 동향 분석 리포트 : 예방 유형별, 최종사용자별, 용도별, 제품 유형별, 지역별 전망과 예측(2023-2030년)

The Global Rabies Vaccine Market size is expected to reach $1.6 billion by 2030, rising at a market growth of 4.5% CAGR during the forecast period.

Pet owners increasingly adopt preventive healthcare practices for their animals, mirroring trends in human healthcare. Regular veterinary visits, including vaccinations, are proactive measures to protect pets from diseases such as rabies, fostering a continuous demand for vaccines. Consequently, the Veterinary clinics segment would acquire nearly, 20% market share by 2030. Advancements in veterinary medicine, including the availability of improved and safer vaccines, contribute to a positive perception of vaccinations among pet owners.

Ongoing R&D activities focus on improving the formulation of these vaccines. Researchers work to enhance vaccine stability, reduce adverse reactions, and optimize the immune response. R&D efforts aim to develop next-generation vaccines with enhanced characteristics. This may include vaccines with longer-lasting immunity, novel delivery methods, and the ability to protect against a broader spectrum of rabies virus variants. Therefore, the market is expanding significantly due to the rising research and development (R&D) initiatives. Additionally, Rabies poses a severe threat to human health as it can be transmitted through the saliva of infected animals, primarily through bites or scratches. Zoonotic diseases often transcend national borders, necessitating global collaboration. Collaborative efforts and funding support facilitate the implementation of vaccination programs to control and eliminate rabies, particularly in regions where the disease poses a significant zoonotic threat. Hence, increasing awareness of zoonotic diseases like rabies has been a pivotal factor in driving the growth of the market.

Moreover, The COVID-19 pandemic disrupted routine healthcare services, including vaccination programs. Lockdowns, restrictions on movement, and healthcare system strain may affect the implementation of rabies vaccination campaigns, particularly in regions with limited resources. Travel restrictions and disruptions in global transportation may affected the movement of professionals involved in global health initiatives and collaborations. This impact global efforts to control and eliminate rabies. Thus, the COVID-19 pandemic had a moderate effect on the market.

However, High vaccination program costs can restrict access to these vaccines, particularly in resource-constrained areas. Governments responsible for public health initiatives may experience financial strain when implementing rabies vaccination programs. The allocation of resources to these programs may compete with other essential healthcare needs, potentially leading to budget constraints. Thus, high cost can slow down the growth of the market.

By Prophylaxis Type Analysis

Based on prophylaxis type, the market is classified into pre-exposure prophylaxis and post-exposure prophylaxis. The pre-exposure prophylaxis segment acquired a 40% revenue share in the market in 2022. Pre-exposure prophylaxis offers long-term protection, reducing the need for immediate post-exposure treatment for potential rabies exposure. This long-term protection can be cost-effective in the long run, considering the expenses associated with post-exposure prophylaxis.

By End User Analysis

Based on end user, the market is segmented into hospitals, veterinary clinics, and others. The veterinary clinics segment recorded a 20% revenue share in the market in 2022. A greater demand for veterinary services, such as rabies vaccination, has resulted from the global rise in the prevalence of pet ownership. Routine vaccination programs are integral to the preventive healthcare veterinary clinics provide to pets, including dogs and cats.

By Application Analysis

On the basis of application, the market is bifurcated into human and animal. The animal segment garnered a 30% revenue share in the market in 2022. Animals, particularly mammals, serve as the primary reservoirs of the rabies virus. Controlling rabies in animal populations is essential to reduce the risk of transmission to humans through bites or scratches.

By Product Type Analysis

By product type, the market is categorized into chick embryo cells rabies vaccine, Vero cell rabies vaccine, human diploid cell vaccine, and others. The Vero cell rabies vaccine segment covered a 20% revenue share in the market in 2022. The Vero cell vaccine eliminates the use of nervous tissue in its production, addressing safety concerns associated with traditional nerve tissue-derived vaccines. Removing nervous tissue reduces the risk of adverse reactions, making the Vero cell vaccine a safer option for rabies prevention.

By Regional Analysis

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating 40% revenue share. North America's health authorities and veterinary services implement strategic vaccination programs targeting domestic and wildlife populations. Veterinary clinics and practices across North America actively participate in rabies prevention by providing pet vaccination services.

List of Key Companies Profiled

• Boehringer Ingelheim International GmbH
• Cadila Pharmaceuticals Limited
• Serum Institute of India Pvt. Ltd. (Cyrus Poonawalla Group)
• Elanco Animal Health, Inc.
• Zoetis, Inc.
• Merck & Co., Inc.
• Novartis AG
• Bharat Biotech Ltd.
• Sanofi S.A.
• Virbac

Global Rabies Vaccine Market Report Segmentation

By Prophylaxis Type

• Post-exposure Prophylaxis
• Pre-exposure prophylaxis

By End User

• Hospitals
• Veterinary Clinics
• Others

By Application

• Human
• Animal

By Product Type

• Chick Embryo Cells Rabies Vaccine
• Human Diploid Cell Vaccine
• Vero cell rabies vaccine
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Rabies Vaccine Market, by Prophylaxis Type
  • 1.4.2Global Rabies Vaccine Market, by End User
  • 1.4.3Global Rabies Vaccine Market, by Application
  • 1.4.4Global Rabies Vaccine Market, by Product Type
  • 1.4.5Global Rabies Vaccine Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Opportunities
  • 3.2.3Market Restraints
  • 3.2.4Market Challenges
• 3.3Porter Five Forces Analysis

Chapter 4.Global Rabies Vaccine Market by Prophylaxis Type

• 4.1Global Post-exposure Prophylaxis Market by Region
• 4.2Global Pre-exposure prophylaxis Market by Region

Chapter 5.Global Rabies Vaccine Market by End User

• 5.1Global Hospitals Market by Region
• 5.2Global Veterinary Clinics Market by Region
• 5.3Global Others Market by Region

Chapter 6.Global Rabies Vaccine Market by Application

• 6.1Global Human Market by Region
• 6.2Global Animal Market by Region

Chapter 7.Global Rabies Vaccine Market by Product Type

• 7.1Global Chick Embryo Cells Rabies Vaccine Market by Region
• 7.2Global Human Diploid Cell Vaccine Market by Region
• 7.3Global Vero Cell Rabies Vaccine Market by Region
• 7.4Global Others Market by Region

Chapter 8.Global Rabies Vaccine Market by Region

• 8.1North America Rabies Vaccine Market
  • 8.1.1North America Rabies Vaccine Market by Prophylaxis Type
    • 8.1.1.1North America Post-exposure Prophylaxis Market by Region
    • 8.1.1.2North America Pre-exposure prophylaxis Market by Region
  • 8.1.2North America Rabies Vaccine Market by End User
    • 8.1.2.1North America Hospitals Market by Country
    • 8.1.2.2North America Veterinary Clinics Market by Country
    • 8.1.2.3North America Others Market by Country
  • 8.1.3North America Rabies Vaccine Market by Application
    • 8.1.3.1North America Human Market by Country
    • 8.1.3.2North America Animal Market by Country
  • 8.1.4North America Rabies Vaccine Market by Product Type
    • 8.1.4.1North America Chick Embryo Cells Rabies Vaccine Market by Country
    • 8.1.4.2North America Human Diploid Cell Vaccine Market by Country
    • 8.1.4.3North America Vero Cell Rabies Vaccine Market by Country
    • 8.1.4.4North America Others Market by Country
  • 8.1.5North America Rabies Vaccine Market by Country
    • 8.1.5.1US Rabies Vaccine Market
      • 8.1.5.1.1US Rabies Vaccine Market by Prophylaxis Type
      • 8.1.5.1.2US Rabies Vaccine Market by End User
      • 8.1.5.1.3US Rabies Vaccine Market by Application
      • 8.1.5.1.4US Rabies Vaccine Market by Product Type
    • 8.1.5.2Canada Rabies Vaccine Market
      • 8.1.5.2.1Canada Rabies Vaccine Market by Prophylaxis Type
      • 8.1.5.2.2Canada Rabies Vaccine Market by End User
      • 8.1.5.2.3Canada Rabies Vaccine Market by Application
      • 8.1.5.2.4Canada Rabies Vaccine Market by Product Type
    • 8.1.5.3Mexico Rabies Vaccine Market
      • 8.1.5.3.1Mexico Rabies Vaccine Market by Prophylaxis Type
      • 8.1.5.3.2Mexico Rabies Vaccine Market by End User
      • 8.1.5.3.3Mexico Rabies Vaccine Market by Application
      • 8.1.5.3.4Mexico Rabies Vaccine Market by Product Type
    • 8.1.5.4Rest of North America Rabies Vaccine Market
      • 8.1.5.4.1Rest of North America Rabies Vaccine Market by Prophylaxis Type
      • 8.1.5.4.2Rest of North America Rabies Vaccine Market by End User
      • 8.1.5.4.3Rest of North America Rabies Vaccine Market by Application
      • 8.1.5.4.4Rest of North America Rabies Vaccine Market by Product Type
• 8.2Europe Rabies Vaccine Market
  • 8.2.1Europe Rabies Vaccine Market by Prophylaxis Type
    • 8.2.1.1Europe Post-exposure Prophylaxis Market by Country
    • 8.2.1.2Europe Pre-exposure prophylaxis Market by Country
  • 8.2.2Europe Rabies Vaccine Market by End User
    • 8.2.2.1Europe Hospitals Market by Country
    • 8.2.2.2Europe Veterinary Clinics Market by Country
    • 8.2.2.3Europe Others Market by Country
  • 8.2.3Europe Rabies Vaccine Market by Application
    • 8.2.3.1Europe Human Market by Country
    • 8.2.3.2Europe Animal Market by Country
  • 8.2.4Europe Rabies Vaccine Market by Product Type
    • 8.2.4.1Europe Chick Embryo Cells Rabies Vaccine Market by Country
    • 8.2.4.2Europe Human Diploid Cell Vaccine Market by Country
    • 8.2.4.3Europe Vero Cell Rabies Vaccine Market by Country
    • 8.2.4.4Europe Others Market by Country
  • 8.2.5Europe Rabies Vaccine Market by Country
    • 8.2.5.1Germany Rabies Vaccine Market
      • 8.2.5.1.1Germany Rabies Vaccine Market by Prophylaxis Type
      • 8.2.5.1.2Germany Rabies Vaccine Market by End User
      • 8.2.5.1.3Germany Rabies Vaccine Market by Application
      • 8.2.5.1.4Germany Rabies Vaccine Market by Product Type
    • 8.2.5.2UK Rabies Vaccine Market
      • 8.2.5.2.1UK Rabies Vaccine Market by Prophylaxis Type
      • 8.2.5.2.2UK Rabies Vaccine Market by End User
      • 8.2.5.2.3UK Rabies Vaccine Market by Application
      • 8.2.5.2.4UK Rabies Vaccine Market by Product Type
    • 8.2.5.3France Rabies Vaccine Market
      • 8.2.5.3.1France Rabies Vaccine Market by Prophylaxis Type
      • 8.2.5.3.2France Rabies Vaccine Market by End User
      • 8.2.5.3.3France Rabies Vaccine Market by Application
      • 8.2.5.3.4France Rabies Vaccine Market by Product Type
    • 8.2.5.4Russia Rabies Vaccine Market
      • 8.2.5.4.1Russia Rabies Vaccine Market by Prophylaxis Type
      • 8.2.5.4.2Russia Rabies Vaccine Market by End User
      • 8.2.5.4.3Russia Rabies Vaccine Market by Application
      • 8.2.5.4.4Russia Rabies Vaccine Market by Product Type
    • 8.2.5.5Spain Rabies Vaccine Market
      • 8.2.5.5.1Spain Rabies Vaccine Market by Prophylaxis Type
      • 8.2.5.5.2Spain Rabies Vaccine Market by End User
      • 8.2.5.5.3Spain Rabies Vaccine Market by Application
      • 8.2.5.5.4Spain Rabies Vaccine Market by Product Type
    • 8.2.5.6Italy Rabies Vaccine Market
      • 8.2.5.6.1Italy Rabies Vaccine Market by Prophylaxis Type
      • 8.2.5.6.2Italy Rabies Vaccine Market by End User
      • 8.2.5.6.3Italy Rabies Vaccine Market by Application
      • 8.2.5.6.4Italy Rabies Vaccine Market by Product Type
    • 8.2.5.7Rest of Europe Rabies Vaccine Market
      • 8.2.5.7.1Rest of Europe Rabies Vaccine Market by Prophylaxis Type
      • 8.2.5.7.2Rest of Europe Rabies Vaccine Market by End User
      • 8.2.5.7.3Rest of Europe Rabies Vaccine Market by Application
      • 8.2.5.7.4Rest of Europe Rabies Vaccine Market by Product Type
• 8.3Asia Pacific Rabies Vaccine Market
  • 8.3.1Asia Pacific Rabies Vaccine Market by Prophylaxis Type
    • 8.3.1.1Asia Pacific Post-exposure Prophylaxis Market by Country
    • 8.3.1.2Asia Pacific Pre-exposure prophylaxis Market by Country
  • 8.3.2Asia Pacific Rabies Vaccine Market by End User
    • 8.3.2.1Asia Pacific Hospitals Market by Country
    • 8.3.2.2Asia Pacific Veterinary Clinics Market by Country
    • 8.3.2.3Asia Pacific Others Market by Country
  • 8.3.3Asia Pacific Rabies Vaccine Market by Application
    • 8.3.3.1Asia Pacific Human Market by Country
    • 8.3.3.2Asia Pacific Animal Market by Country
  • 8.3.4Asia Pacific Rabies Vaccine Market by Product Type
    • 8.3.4.1Asia Pacific Chick Embryo Cells Rabies Vaccine Market by Country
    • 8.3.4.2Asia Pacific Human Diploid Cell Vaccine Market by Country
    • 8.3.4.3Asia Pacific Vero Cell Rabies Vaccine Market by Country
    • 8.3.4.4Asia Pacific Others Market by Country
  • 8.3.5Asia Pacific Rabies Vaccine Market by Country
    • 8.3.5.1China Rabies Vaccine Market
      • 8.3.5.1.1China Rabies Vaccine Market by Prophylaxis Type
      • 8.3.5.1.2China Rabies Vaccine Market by End User
      • 8.3.5.1.3China Rabies Vaccine Market by Application
      • 8.3.5.1.4China Rabies Vaccine Market by Product Type
    • 8.3.5.2Japan Rabies Vaccine Market
      • 8.3.5.2.1Japan Rabies Vaccine Market by Prophylaxis Type
      • 8.3.5.2.2Japan Rabies Vaccine Market by End User
      • 8.3.5.2.3Japan Rabies Vaccine Market by Application
      • 8.3.5.2.4Japan Rabies Vaccine Market by Product Type
    • 8.3.5.3India Rabies Vaccine Market
      • 8.3.5.3.1India Rabies Vaccine Market by Prophylaxis Type
      • 8.3.5.3.2India Rabies Vaccine Market by End User
      • 8.3.5.3.3India Rabies Vaccine Market by Application
      • 8.3.5.3.4India Rabies Vaccine Market by Product Type
    • 8.3.5.4South Korea Rabies Vaccine Market
      • 8.3.5.4.1South Korea Rabies Vaccine Market by Prophylaxis Type
      • 8.3.5.4.2South Korea Rabies Vaccine Market by End User
      • 8.3.5.4.3South Korea Rabies Vaccine Market by Application
      • 8.3.5.4.4South Korea Rabies Vaccine Market by Product Type
    • 8.3.5.5Singapore Rabies Vaccine Market
      • 8.3.5.5.1Singapore Rabies Vaccine Market by Prophylaxis Type
      • 8.3.5.5.2Singapore Rabies Vaccine Market by End User
      • 8.3.5.5.3Singapore Rabies Vaccine Market by Application
      • 8.3.5.5.4Singapore Rabies Vaccine Market by Product Type
    • 8.3.5.6Malaysia Rabies Vaccine Market
      • 8.3.5.6.1Malaysia Rabies Vaccine Market by Prophylaxis Type
      • 8.3.5.6.2Malaysia Rabies Vaccine Market by End User
      • 8.3.5.6.3Malaysia Rabies Vaccine Market by Application
      • 8.3.5.6.4Malaysia Rabies Vaccine Market by Product Type
    • 8.3.5.7Rest of Asia Pacific Rabies Vaccine Market
      • 8.3.5.7.1Rest of Asia Pacific Rabies Vaccine Market by Prophylaxis Type
      • 8.3.5.7.2Rest of Asia Pacific Rabies Vaccine Market by End User
      • 8.3.5.7.3Rest of Asia Pacific Rabies Vaccine Market by Application
      • 8.3.5.7.4Rest of Asia Pacific Rabies Vaccine Market by Product Type
• 8.4LAMEA Rabies Vaccine Market
  • 8.4.1LAMEA Rabies Vaccine Market by Prophylaxis Type
    • 8.4.1.1LAMEA Post-exposure Prophylaxis Market by Country
    • 8.4.1.2LAMEA Pre-exposure prophylaxis Market by Country
  • 8.4.2LAMEA Rabies Vaccine Market by End User
    • 8.4.2.1LAMEA Hospitals Market by Country
    • 8.4.2.2LAMEA Veterinary Clinics Market by Country
    • 8.4.2.3LAMEA Others Market by Country
  • 8.4.3LAMEA Rabies Vaccine Market by Application
    • 8.4.3.1LAMEA Human Market by Country
    • 8.4.3.2LAMEA Animal Market by Country
  • 8.4.4LAMEA Rabies Vaccine Market by Product Type
    • 8.4.4.1LAMEA Chick Embryo Cells Rabies Vaccine Market by Country
    • 8.4.4.2LAMEA Human Diploid Cell Vaccine Market by Country
    • 8.4.4.3LAMEA Vero Cell Rabies Vaccine Market by Country
    • 8.4.4.4LAMEA Others Market by Country
  • 8.4.5LAMEA Rabies Vaccine Market by Country
    • 8.4.5.1Brazil Rabies Vaccine Market
      • 8.4.5.1.1Brazil Rabies Vaccine Market by Prophylaxis Type
      • 8.4.5.1.2Brazil Rabies Vaccine Market by End User
      • 8.4.5.1.3Brazil Rabies Vaccine Market by Application
      • 8.4.5.1.4Brazil Rabies Vaccine Market by Product Type
    • 8.4.5.2Argentina Rabies Vaccine Market
      • 8.4.5.2.1Argentina Rabies Vaccine Market by Prophylaxis Type
      • 8.4.5.2.2Argentina Rabies Vaccine Market by End User
      • 8.4.5.2.3Argentina Rabies Vaccine Market by Application
      • 8.4.5.2.4Argentina Rabies Vaccine Market by Product Type
    • 8.4.5.3UAE Rabies Vaccine Market
      • 8.4.5.3.1UAE Rabies Vaccine Market by Prophylaxis Type
      • 8.4.5.3.2UAE Rabies Vaccine Market by End User
      • 8.4.5.3.3UAE Rabies Vaccine Market by Application
      • 8.4.5.3.4UAE Rabies Vaccine Market by Product Type
    • 8.4.5.4Saudi Arabia Rabies Vaccine Market
      • 8.4.5.4.1Saudi Arabia Rabies Vaccine Market by Prophylaxis Type
      • 8.4.5.4.2Saudi Arabia Rabies Vaccine Market by End User
      • 8.4.5.4.3Saudi Arabia Rabies Vaccine Market by Application
      • 8.4.5.4.4Saudi Arabia Rabies Vaccine Market by Product Type
    • 8.4.5.5South Africa Rabies Vaccine Market
      • 8.4.5.5.1South Africa Rabies Vaccine Market by Prophylaxis Type
      • 8.4.5.5.2South Africa Rabies Vaccine Market by End User
      • 8.4.5.5.3South Africa Rabies Vaccine Market by Application
      • 8.4.5.5.4South Africa Rabies Vaccine Market by Product Type
    • 8.4.5.6Nigeria Rabies Vaccine Market
      • 8.4.5.6.1Nigeria Rabies Vaccine Market by Prophylaxis Type
      • 8.4.5.6.2Nigeria Rabies Vaccine Market by End User
      • 8.4.5.6.3Nigeria Rabies Vaccine Market by Application
      • 8.4.5.6.4Nigeria Rabies Vaccine Market by Product Type
    • 8.4.5.7Rest of LAMEA Rabies Vaccine Market
      • 8.4.5.7.1Rest of LAMEA Rabies Vaccine Market by Prophylaxis Type
      • 8.4.5.7.2Rest of LAMEA Rabies Vaccine Market by End User
      • 8.4.5.7.3Rest of LAMEA Rabies Vaccine Market by Application
      • 8.4.5.7.4Rest of LAMEA Rabies Vaccine Market by Product Type

Chapter 9.Company Profiles

• 9.1Cadila Pharmaceuticals Limited
  • 9.1.1Company Overview
  • 9.1.2Recent strategies and developments:
    • 9.1.2.1Product Launches and Product Expansions:
• 9.2Bharat Biotech Ltd.
  • 9.2.1Company Overview
• 9.3Serum Institute of India Pvt. Ltd. (Cyrus Poonawalla Group)
  • 9.3.1Company Overview
• 9.4Boehringer Ingelheim International GmbH
  • 9.4.1Company Overview
  • 9.4.2Financial Analysis
  • 9.4.3Regional & Segmental Analysis
  • 9.4.4Research & Development Expenses
  • 9.4.5SWOT Analysis
• 9.5Elanco Animal Health, Inc.
  • 9.5.1Company Overview
  • 9.5.2Financial Analysis
  • 9.5.3Regional Analysis
  • 9.5.4Research & Development Expense
  • 9.5.5SWOT Analysis
• 9.6Zoetis, Inc.
  • 9.6.1Company Overview
  • 9.6.2Financial Analysis
  • 9.6.3Regional Analysis
  • 9.6.4Research & Development Expense
  • 9.6.5SWOT Analysis
• 9.7Merck & Co., Inc.
  • 9.7.1Company Overview
  • 9.7.2Financial Analysis
  • 9.7.3Segmental and Regional Analysis
  • 9.7.4Research & Development Expenses
  • 9.7.5SWOT Analysis
• 9.8Novartis AG
  • 9.8.1Company Overview
  • 9.8.2Financial Analysis
  • 9.8.3Segmental and Regional Analysis
  • 9.8.4Research & Development Expense
  • 9.8.5SWOT Analysis
• 9.9Sanofi S.A.
  • 9.9.1Company Overview
  • 9.9.2Financial Analysis
  • 9.9.3Segmental and Regional Analysis
  • 9.9.4Research & Development Expense
  • 9.9.5SWOT Analysis
• 9.10.Virbac
  • 9.10.1Company Overview
  • 9.10.2Financial Analysis
  • 9.10.3Regional Analysis
  • 9.10.4SWOT Analysis

Chapter 10.Winning imperative of Rabies Vaccine Market